Finding the right dose of burosumab for XLH
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how young people with X-linked hypophosphataemia (XLH) respond to different doses of burosumab. The goal is to find the best dose to manage the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have XLH caused by a confirmed PHEX gene change.
- You must have been taking burosumab continuously for at least 12 months before your 18th birthday.
- Your burosumab treatment must have started when you were a child (not when you were an adult).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides access to a medication called burosumab (Crysvita) for people with a rare genetic condition called X-linked hypophosphatemia (XLH), which causes weak bones and low phosphate levels. It is designed for those who cannot get the drug through normal channels or other clinical trials.
This registry collects information about people diagnosed with X-linked hypophosphatemia (XLH). It helps researchers better understand the condition and may support future studies by tracking patients over time.
This study tests an investigational drug called KK8123 for adults with X-linked hypophosphatemia (XLH), a rare condition that causes low phosphate levels and can lead to bone problems. The goal is to see if it helps improve phosphate levels in the body.
This study tests whether burosumab and vitamin D affect bone cells before and around the time of craniosynostosis surgery in children. It may help researchers understand treatment options for rare calcium and phosphate bone disorders that can affect skull growth.
This early study looks at how the body’s handling of phosphate may affect aging and bone health. It is meant for people with certain rare genetic conditions that change phosphate levels, to better understand their biology and responses to study tests.
This study tests a new pill (FXS6837) against a standard treatment (eculizumab) for people with PNH. The goal is to see if the pill is safe and effective in improving anemia and reducing the need for transfusions.
Hear when a new X-linked Hypophosphatemia (XLH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.